An early clinical trial of the once-daily pill daraxonrasib plus standard chemotherapy shrank or cleared tumors in 60.7% of patients starting treatment for metastatic pancreatic cancer, Revolution Medicines and Memorial Sloan Kettering’s Dr. Wungki Park reported.

The updated results, from the open-label Phase 1/2 RMC-GI-102 study, were presented at the EORTC-NCI-AACR symposium in Barcelona. As of a Sept. 28, 2026, data cutoff, 61 patients in the first-line metastatic pancreatic adenocarcinoma cohort had received daraxonrasib — sold as Rasonque — at 200 mg plus gemcitabine and nab-paclitaxel, with a median follow-up of 18.3 months, the company said in a Nov. 19 news release.

The confirmed objective response rate was 60.7%, including complete responses in 8.2% of patients, or about 1 in 12, meaning tumors were no longer detectable on scans. The disease control rate was 90.2%. Median duration of response was 11.1 months. Median progression-free survival was 12.8 months, and 12-month overall survival was 76.6%. The company said the safety profile was consistent with the known profiles of both drugs.

Is It a Cure?

Dr. Wungki Park, a medical oncologist at Memorial Sloan Kettering’s David M. Rubenstein Center for Pancreatic Cancer Research and an investigator on the study, presented the data. In the company release he described “deep complete responses” and “durable disease control, with median progression-free survival exceeding one year,” and said the findings “provide a compelling rationale to further evaluate daraxonrasib as a potential first-line treatment option.”

Speaking to the Press Association, Park called the results “a massive, massive breakthrough” and said, “We’ve never seen such a thing.” Asked whether the patients whose tumors could no longer be seen were cured, he said, “This is the closest to a cure.” A complete response on a scan is not the same as a cure; the disease can still return. The BBC reported that doctors stress the results should not be seen as a cure and that longer follow-up is needed.

This was an early study, and a Phase 3 trial is already underway

The Phase 1/2 study was open-label and had no chemotherapy-only comparison group, so these results cannot, by themselves, prove the combination is better than standard chemotherapy. The drug is already FDA-approved in the United States for some patients with metastatic pancreatic cancer after prior therapy, or who cannot receive multiagent therapy. Using it with chemotherapy as a first-line treatment remains investigational. The FDA has granted Breakthrough Therapy Designation for that first-line combination, Revolution Medicines said.

A global Phase 3 trial, RASolute 303, is already underway. It is comparing daraxonrasib alone, daraxonrasib plus the same chemotherapy, and chemotherapy alone in patients with previously untreated metastatic pancreatic cancer, according to the company and ClinicalTrials.gov.

Dr. Madina Kara, head of research at Pancreatic Cancer UK, called this “a small, initial study” with “encouraging results” and said a larger trial is needed. Cancer Research UK chief executive Michelle Mitchell said more trials are needed before the treatment can be assessed for wider use, and that pancreatic cancer survival is still very low.

What we know

  • Phase 1/2 RMC-GI-102 enrolled 61 first-line metastatic pancreatic cancer patients on daraxonrasib 200 mg plus gemcitabine and nab-paclitaxel.
  • Confirmed response rate 60.7%, including complete responses in 8.2%; disease control rate 90.2%.
  • Median progression-free survival 12.8 months; 12-month overall survival 76.6%; median follow-up 18.3 months.
  • The study was open-label and had no chemotherapy-only comparison arm. A Phase 3 trial, RASolute 303, is underway.

What we don’t know

  • How long complete responses will last, and whether any of those patients will stay in remission.
  • Whether the combination will beat standard chemotherapy in the randomized Phase 3 trial.
  • The full, detailed safety results for this first-line combination, beyond the company’s statement that they were consistent with known profiles.

Sources: Revolution Medicines news release, Nov. 19, 2026; Dr. Wungki Park, Memorial Sloan Kettering Cancer Center, ENA 2026 presentation and Press Association interview; ClinicalTrials.gov NCT07491445; Revolution Medicines, FDA Breakthrough Therapy Designation announcement, Sept. 14, 2026; Dr. Madina Kara, Pancreatic Cancer UK; Michelle Mitchell, Cancer Research UK; BBC News. CT scans: Dr. Michael May / Dr. Wungki Park / Memorial Sloan Kettering Cancer Center / Press Association.

Follow First Feed News on Facebook for breaking news first.

Watch the First Feed News video report on Facebook

Leave a Reply

Trending